• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DIA, Korea National Enterprise for Clinical Trials ink MoU

DIA, Korea National Enterprise for Clinical Trials ink MoU

October 3, 2014
CenterWatch Staff

Korea National Enterprise for Clinical Trials (KoNECT) and DIA (Drug Information Association), based in Washington, D.C., have signed a Memorandum of Understanding (MoU) to establish a cooperative relationship and explore collaboration in development of training, education and knowledge exchange opportunities.

Both organizations have an interest in delivering educational offerings through classroom and on-line training courses, along with additional opportunities to further develop and advance innovations in therapeutic product development.

KoNECT was established in April as a nonprofit foundation by the Korean Ministry of Health and Welfare for furthering development of clinical trial infrastructure and capability, to establish Korea as a global clinical trial hub and preferred partner for drug development in the Asia Pacific region, as the continuum of the 1st KoNECT established in December 2007.

DIA was established in 1964 as a nonprofit neutral forum to increase communication and collaboration in drug development in order to improve product safety and efficacy and to advance therapeutic successes.

Dr. Deborah Chee, KoNECT’s president, said, “We are delighted to sign an MOU with DIA, reinforcing bilateral collaboration between DIA and Korea, with a common ultimate goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients. Together with DIA, KoNECT hopes to provide high-quality training to Korean clinical trial professionals and in the process, help to advance their competency.”

Barbara Lopez Kunz, DIA’s global chief executive, said, “DIA is excited about the possibility of expanding our impact in Korea. This collaboration with KoNECT provides us with access to a network of partners and the opportunity to make a positive difference in helping to bring safe and effective health therapies to the Korean market and to the patients served.” 

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing